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Abstract
Prions adopt alternative, self-replicating protein conformations and thereby determine novel
phenotypes that are often irreversible. Nevertheless, dominant-negative prion mutants can
revert phenotypes associated with some conformations. These observations suggest that,
while intervention is possible, distinct inhibitors must be developed to overcome the confor-
mational plasticity of prions. To understand the basis of this specificity, we determined the
impact of the G58D mutant of the Sup35 prion on three of its conformational variants, which
form amyloids in S. cerevisiae. G58D had been previously proposed to have unique effects
on these variants, but our studies suggest a common mechanism. All variants, including
those reported to be resistant, are inhibited by G58D but at distinct doses. G58D lowers the
kinetic stability of the associated amyloid, enhancing its fragmentation by molecular chaper-
ones, promoting Sup35 resolubilization, and leading to amyloid clearance particularly in
daughter cells. Reducing the availability or activity of the chaperone Hsp104, even tran-
siently, reverses curing. Thus, the specificity of inhibition is determined by the sensitivity of
variants to the mutant dosage rather than mode of action, challenging the view that a unique
inhibitor must be developed to combat each variant.
Author summary
Prion proteins adopt alternative conformations and assemble into amyloid fibers, which
have been associated with human disease. These fibers are highly stable and self-replicate,
leading to their persistence and resulting in a set of progressive and often fatal disorders.
Inhibitors have been shown to interfere with some conformations but not others, suggest-
ing that distinct strategies must be developed to target each. However, we show here that a
single dominant-negative mutant can inhibit multiple conformations of the same prion
protein through the same pathway but at distinct doses. Thus, the basis of this specificity
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is sensitivity rather than resistance to the mechanism of inhibition, suggesting that com-
mon strategies may be used to target a range of prion conformations.
Introduction
Alternative, self-replicating protein conformations have emerged as bona fide parallel protein-
folding trajectories with significant biological consequences [1]. In most cases, these alterna-
tive conformations are β-sheet-rich and self-assembling, forming linear amyloid aggregates
[2]. These amyloids replicate the conformation of their constituent monomers by acting as
templates to direct the refolding of other conformers of the same protein as they are bound by
and incorporated into the growing aggregate. In so doing, the majority of the protein is con-
verted to the alternative conformation, changing protein activity and thereby inducing new
phenotypes, such as neurodegenerative diseases (i.e., Transmissible Spongiform Encephalopa-
thies or prion diseases, Alzheimer’s and Huntington’s diseases) and organelle biogenesis in
mammals and gene expression regulation in single-celled organisms [1,3]. The high efficiency
of this process, when combined with the high kinetic stability of the aggregates [2], contributes
to the recalcitrance of amyloids to clearance by protein quality control pathways [4]. As a
result, the associated phenotypes are frequently difficult—if not impossible—to reverse, espe-
cially in the clinic [5].
One notable exception to the persistence of amyloid-associated phenotypes is their reversal
or “curing” by dominant-negative mutants of prion proteins. These sequence variants were
first identified by their ability to confer resistance to scrapie in sheep (Q171R or R154H in the
mammalian prion protein PrP), sporadic Creutzfeldt-Jakob disease (sCJD) in humans (E219K
in PrP), and translation termination infidelity in yeast (G58D in Sup35) [6–19]. Subsequently,
these mutants were shown to interfere with the assembly of amyloid by the wildtype prion pro-
tein in vitro and to reduce or clear existing amyloid composed of the wildtype prion protein
when delivered to tissue culture cells, mice, or yeast [15,19–31]. Given this unique curing abil-
ity, elucidating the mechanism(s) by which dominant-negative prion mutants act may reveal
potential strategies for reversing amyloid persistence more generally.
Despite the promise of this line of investigation, the inhibition achieved by dominant-nega-
tive mutants appears to be conformation-specific. For example, the resistance to sCJD con-
ferred by the E219K PrP mutant in humans is not extended to the conformations, known as
variants, responsible for genetic and iatrogenic forms of the disease [14,15,17,32–35]. Simi-
larly, resistance to classical scrapie is not observed for bovine spongiform encephalopathy
(BSE) or atypical scrapie variants in sheep with Q171R or R154H mutations in PrP [10,36–43]
[44–52]. Finally, the G58D mutation of Sup35 cures the [PSI+]Strong and [PSI+]Sc4 variants (n.b.
[PSI+] denotes the transmissible amyloid state of Sup35) to different extents in different
genetic backgrounds but is unable to cure the [PSI+]Sc37 and [PSI+]Weak variants in yeast
[53,54].
What is the molecular basis of this differential inhibition? One possibility is that the distinct
recognition surfaces and/or rate-limiting steps in the self-replication process characteristic of
the variants make them susceptible to only certain mechanisms of inhibition [55–61]. Alterna-
tively, the conformational differences may confer distinct sensitivities to the same mechanism
of inhibition. Given the conformational plasticity of amyloidogenic proteins [62,63], under-
standing the forces limiting the efficacy of inhibitors can mean the difference between develop-
ing an infinite number of individual interventions for each variant or simply different dosing
regimes for the same inhibitor.
A common mechanism of DN prion inhibition
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Here, we exploit the yeast prion Sup35 to gain this insight. We explored the sensitivity of
three variants of Sup35 (i.e., [PSI+]Sc4, [PSI+]Weak, and [PSI+]Sc37) to expression of G58D and
the impact of this dominant-negative mutant on the self-replication of each variant. Our stud-
ies indicate that “resistance” to G58D can be partially overcome at higher dosage of the
mutant, revealing differential sensitivity to the inhibition. G58D reduces the kinetic stabilities
of the amyloids associated with the variants, which determines their efficiencies of fragmenta-
tion by chaperones [60]. Consistent with this correlation, G58D inhibition of the three variants
was dependent on the chaperone Hsp104, as was the case for the previously studied [PSI+]Strong
variant [64]. In the presence of G58D, Sup35 amyloid was fragmented by Hsp104 with higher
efficiency. This increase led to amyloid clearance in daughter cells, which could be reversed by
transient inhibition of Hsp104 specifically in this population. Thus, G58D dominant-negative
inhibition targets distinct conformational variants through the same mechanism with differing
efficacy, suggesting that the observed “resistance” is relative rather than absolute.
Results
[PSI+] variants are inhibited at distinct doses of G58D
To determine if the specificity of G58D on [PSI+] variants occurs through distinct mechanisms
or through distinct sensitivities to the same mechanism of inhibition, we generated diploid
[PSI+]Sc4, [PSI+]Weak and [PSI+]Sc37 yeast strains expressing wildtype Sup35 at different ratios
relative to G58D (2:1, 1:1, 1:2; S1 Fig). Inhibition of [PSI+] propagation can be monitored func-
tionally because the formation of amyloid by Sup35 partially compromises its activity and
leads to a defect in translation termination [65,66]. [PSI+] strains carrying the ade1-14 allele
form white colonies on rich medium due to read-through of a premature stop codon in the
ADE1 open reading frame. However, strains with defective prion propagation, or those that
have lost the prion state (known as [psi-]), form red colonies on rich medium as a result of the
accumulation of active Sup35 [67].
Expression of G58D at any ratio in a [PSI+]Sc4 strain promoted the accumulation of red pig-
ment on rich medium, indicating reversal of the prion phenotype (Fig 1A). By colony color,
the severity of this effect increased with G58D dosage, with a 1:2 ratio of wildtype to G58D
leading to a colony phenotype for [PSI+]Sc4 that was indistinguishable from [psi-] (Fig 1A). For
the [PSI+]Sc37 and [PSI+]Weak variants, which were previously reported to be compatible with
G58D expression [53,54], efficient prion propagation was also dependent on the ratio of wild-
type to G58D, but the critical threshold for phenotypic reversal was distinct in each case. The
[PSI+]Sc37 variant formed colonies that were more pink on rich medium at a 1:1 ratio of wild-
type to G58D relative to a wildtype strain and that were indistinguishable from [psi-] at a 1:2
ratio of wildtype to G58D (Fig 1B), mirroring our observations for [PSI+]Sc4 (Fig 1A). In con-
trast, the [PSI+]Weak variant phenotype was only partially reversed at the highest ratio of wild-
type to G58D tested (1:2), where the pinker colonies on rich medium relative to the wildtype
[PSI+]Weak strain indicated a mild inhibition by G58D (Fig 1C). Thus, the three [PSI+] variants
are each dominantly inhibited by G58D expression in a dose-dependent manner, but the dose
required for inhibition of [PSI+]Sc4 and [PSI+]Sc37 is lower than that of [PSI+]Weak.
To assess whether reversal of the [PSI+] phenotype upon G58D expression reflected prion
loss (i.e., curing), we determined the frequencies of [psi-] appearance during mitotic division
for each strain. [PSI+] propagation was largely stable at the 2:1 (~0% curing) and 1:1 (~1% cur-
ing) ratios of wildtype to G58D for both [PSI+]Sc4 and [PSI+]Sc37, where the colony phenotype
was only mildly reversed (Fig 1A, 1B, 1D and 1E). At a 1:2 ratio of wildtype to G58D, both
[PSI+]Sc4 (~9% curing, Fig 1D) and [PSI+]Sc37 (~8% curing, Fig 1E) were more unstable, consis-
tent with the stronger reversal of their prion phenotypes at this ratio (Fig 1A and 1B). For the
A common mechanism of DN prion inhibition
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Fig 1. Dose-dependent effects of G58D expression on [PSI+] variants. [PSI+]Sc4 (A), [PSI+]Sc37 (B) and [PSI+]Weak (C)
wildtype (HSP104/+) or heterozygous-disruption (HSP104/Δ) diploid strains expressing wildtype (WT) and G58D Sup35
from PSUP35 at the indicated ratios were spotted on rich medium to analyze the [PSI+] phenotype. [psi-] diploids were
included as controls. Spontaneous frequencies of [PSI+]Sc4 (D), [PSI+]Sc37 (E) and [PSI+]Weak (F) loss during mitotic
division were determined by counting the percentage of [psi-] colonies. For each strain, >3000 colonies were scored. Error
bars represent standard deviations from 12 biological replicates.
https://doi.org/10.1371/journal.pgen.1007085.g001
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[PSI+]Weak variant, which is less sensitive to G58D inhibition (Fig 1C), [PSI+] propagation was
stable at all wildtype:G58D ratios tested (Fig 1F). Thus, [PSI+] curing in diploids expressing
G58D parallels the severity of the phenotypic reversal in all three variants and, for the most sen-
sitive strains (i.e., [PSI+]Sc4 and [PSI+]Sc37), arises in a dose-dependent manner. Together, these
observations indicate that the previously described “resistance” of [PSI+]Sc37 and [PSI+]Weak to
curing by G58D expression reflected their higher threshold for sensitivity rather than their
absolute recalcitrance to inhibition by this mutant.
G58D reduces the kinetic stability of Sup35 aggregates from all [PSI+]
variants
Although the three [PSI+] variants studied here, in addition to the previously studied [PSI+]Strong
variant [64], differ in their sensitivities to G58D inhibition (Fig 1), the dose dependence of
this inhibition suggests a common underlying mechanism [64,68]. We previously linked G58D
inhibition to a reduction in the kinetic stability of Sup35 aggregates and a resulting increase in
their fragmentation by the chaperone Hsp104, which led to their disassembly [64]. In this
model, the distinct effective inhibitory ratios of G58D on [PSI+] variants may reflect the impact
that this mutant has on the kinetic stability of each. While it has been well-established that
Sup35 aggregates in the [PSI+]Sc4 conformation are of lower stability than those in the [PSI+]Sc37
conformation, the relative stabilities of the four variants have not been previously reported
[60,69,70].
To gain this insight, we first determined the kinetic stabilities of Sup35 aggregates, in the
absence of G58D, by their sensitivity to disruption with 2% SDS at different temperatures as a
baseline comparison [71]. Solubilized protein is then quantified by entry into a SDS-polyacryl-
amide gel and immunoblotting [64]. For wildtype strains, Sup35 was efficiently released from
aggregates between 65˚C and 75˚C in lysates from strains propagating the [PSI+]Strong and
[PSI+]Sc4 variants (Fig 2A) or between 70˚C and 90˚C in lysates from strains propagating the
[PSI+]Weak and [PSI+]Sc37 variants (Fig 2B). The higher kinetic stability of the latter variants is
consistent with their lower efficiency of fragmentation, which leads to a larger steady-state size
for their associated amyloids as assessed by semi-denaturing agarose gel electrophoresis
(SDD-AGE) and immunoblotting for Sup35 (S2 Fig) [60,72].
To sensitize the assay in an attempt to reveal biochemical differences between the variants
in each group, we deleted the NATA N-terminal acetyltransferase, which reduces the kinetic
stability of Sup35 amyloid in [PSI+] strains [73,74]. In this genetic background, the fraction of
soluble Sup35 released from amyloid of the [PSI+]Strong variant in the presence of SDS was sig-
nificantly increased relative to that from the [PSI+]Sc4 variant over the same temperature range
(Fig 2C), indicating that the aggregates are less kinetically stable in the [PSI+]Strong than the
[PSI+]Sc4 variant. Similarly, a significantly larger fraction of Sup35 was released from amyloid
in the presence of SDS from the [PSI+]Sc37 variant than from the [PSI+]Weak variant (Fig 2D),
indicating that the aggregates are less kinetically stable in the [PSI+]Sc37 than the [PSI+]Weak
variant. Thus, the kinetic stability of Sup35 aggregates in [PSI+] variants increases in the order
[PSI+]Strong, [PSI+]Sc4, [PSI+]Sc37, [PSI+]Weak.
If G58D inhibits these variants through a common mechanism, we would expect the kinetic
stabilities of each of the variants to decrease in the presence of the mutant. To test this possibil-
ity, we assessed the sensitivity of Sup35 aggregates, isolated from diploid strains expressing a
1:1 ratio of wildtype to G58D, to disruption with 2% SDS at different temperatures. Soluble
protein was then quantified by entry into an SDS-polyacrylamide gel and immunoblotting for
Sup35. For the [PSI+]Sc4 strain, G58D expression increased the amount of soluble Sup35
released from aggregates at all temperatures assayed (65˚C, 70˚C and 75˚C) in comparison
A common mechanism of DN prion inhibition
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with a wildtype strain (Fig 3A). G58D similarly promoted Sup35 release from aggregates iso-
lated from the [PSI+]Sc37 (Fig 3B) and [PSI+]Weak (Fig 3C) strains at 80˚C and 85˚C, but the
magnitude of this effect was greater for the former. Thus, G58D incorporation destabilizes
Sup35 aggregates from [PSI+] variants in a manner that correlates directly with the severity of
their phenotypic inhibition (Fig 1). These observations are consistent with the idea that G58D
acts through a similar mechanism to inhibit the [PSI+] variants.
Fig 2. Analysis of aggregate properties for [PSI+] variants. Lysates from [PSI+]Strong and [PSI+]Sc4 WT
(A), [PSI+]Weak and [PSI+]Sc37 WT (B), [PSI+]Strong and [PSI+]Sc4 ΔNATA (C) or [PSI+]Weak and [PSI+]Sc37
ΔNATA (D) haploid strains were incubated in SDS at the indicated temperatures before SDS-PAGE and
quantitative immunoblotting for Sup35 (percentage of Sup35 released from aggregates at the indicated
temperatures). Horizontal lines on boxes indicate 25th, 50th and 75th percentiles; whiskers indicate 10th and
90th percentiles. Horizontal lines indicate pair-wise comparisons (n4; paired t-test, *P<0.05).
https://doi.org/10.1371/journal.pgen.1007085.g002
A common mechanism of DN prion inhibition
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Fig 3. Effects of G58D and HSP104 dosage on Sup35 aggregate properties. Lysates from [PSI+]Sc4 (A), [PSI+]Sc37 (B) or
[PSI+]Weak (C) diploid strains expressing one endogenous copy of SUP35 and a second copy of SUP35 (WT or G58D) from
PSUP35 were incubated in SDS at the indicated temperatures before SDS-PAGE and quantitative immunoblotting for Sup35
(percentage of Sup35 released from aggregates at the indicated temperatures). Box plots are as described in the legend to
Fig 2. Horizontal lines indicate pair-wise comparisons (n5; paired t-test, *P<0.05, **P<0.05, ***P<0.001). Lysates of
[PSI+]Sc4 (D), [PSI+]Sc37 (E) or [PSI+]Weak (F) diploid strains expressing Sup35 (WT) and G58D in the indicated ratios were
A common mechanism of DN prion inhibition
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Dominant inhibition of [PSI+] variants by G58D depends on Hsp104
A decrease in the kinetic stability of amyloid should increase its efficiency of fragmentation
and potentially lead to its clearance. To begin to determine the effects of G58D on the frag-
mentation of Sup35 amyloid associated with these [PSI+] variants, we first assessed the steady-
state size distributions of these complexes by SDD-AGE and immunoblotting for Sup35. As
we have previously observed for [PSI+]Strong [64], expression of G58D at any ratio relative to
wildtype Sup35 in a [PSI+]Sc4 strain led to a decrease in the accumulation of slowly migrating
aggregates in comparison to the same dose of wildtype protein alone (Fig 3D). For [PSI+]Sc37,
similar decreases were observed (Fig 3E), but for [PSI+]Weak, Sup35 aggregates were only
shifted to smaller complexes at the lowest wildtype to G58D ratio tested (1:2, Fig 3F). Together,
these observations suggest that the kinetic destabilization of Sup35 aggregates by G58D results
in a higher efficiency of fragmentation in vivo, and these effects correlate directly with the
severity of their phenotypic inhibition (Fig 1).
To determine how the kinetic destabilization of Sup35 aggregates by G58D impacts the
number of heritable prion units (propagons) in [PSI+]Sc4, [PSI+]Sc37 and [PSI+]Weak strains, we
used a genetic assay [75]. Specifically, diploid strains expressing either two copies of wildtype
SUP35 or one copy each of wildtype SUP35 and G58D were treated with guanidine HCl
(GdnHCl), a potent inhibitor of the fragmentation catalyst Hsp104 [67,76–81], allowed to
dilute existing aggregates through cell division, and plated in the absence of the inhibitor to
quantify the number of cells inheriting an aggregate. As we have previously observed in a
[PSI+]Strong strain [64], G58D expression in either [PSI+]Sc4 and [PSI+]Sc37 diploids reduced
propagon number by factors of ~2 and ~4, respectively (Fig 3G and 3H), consistent with the
reversal of the [PSI+] phenotype and the loss of [PSI+] that we observed in these strains (Fig
1A, 1B, 1D and 1E). In contrast, G58D expression in [PSI+]Weak increased propagon number
by a factor of ~2.5 (Fig 3I). Although we did not detect any changes in the severity or stability
of the [PSI+]Weak phenotype at this ratio (Fig 1C and 1F), this increase in propagon count pro-
vides an explanation for the previously reported strengthening of the [PSI+]Weak phenotype
upon G58D expression to much higher levels [53]. Phenotypic strengthening is associated
with a decrease in soluble Sup35, which would result from an increase in amyloid templates,
detected as propagons in this assay, through enhanced fragmentation [60]. Thus, the pheno-
typic consequences of G58D expression, both inhibition and enhancement, can be directly
explained by changes in the steady-state accumulation of Sup35 propagons. Given the distinct
kinetic stabilities of Sup35 amyloid in the [PSI+] variants studied here (Fig 2), the specificity of
G58D inhibition and enhancement likely reflect thresholds for fragmentation activity that
result in changes in the steady-state accumulation of Sup35 forms in vivo.
If enhanced fragmentation is indeed the mechanism underlying G58D effects, these
changes should be Hsp104-dependent. To determine if this is the case, we constructed hetero-
zygous disruptions of HSP104 in diploid strains expressing G58D at different ratios (S3 Fig).
In strains expressing only wildtype Sup35, heterozygous disruption of HSP104 significantly
decreased the number of propagons in the [PSI+]Sc4 and [PSI+]Sc37 variants tested (Fig 3G and
3H, compare lanes 1 and 3), consistent with its catalytic role in fragmentation [78,79] and the
size threshold for Sup35 aggregate transmission [72]. In contrast, heterozygous disruption of
analyzed by SDD-AGE and immunoblotting for Sup35. For [PSI+]Sc4 (G), [PSI+]Sc37 (H) or [PSI+]Weak (I), the number of
propagons present in individual cells was counted in wildype (+) and heterozygous HSP104 disruption (Δ) strains, and the
ratio of propagons relative to WT was determined in diploid strains expressing one endogenous copy of SUP35 and one copy
of SUP35 (WT or G58D) from PSUP35. Box plots are as described in the legend to Fig 2. Horizontal lines indicate pair-wise
comparisons (n10 cells per strain; unpaired t-test, *P<0.05, ***P<0.001).
https://doi.org/10.1371/journal.pgen.1007085.g003
A common mechanism of DN prion inhibition
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HSP104 in [PSI+] variant strains expressing both wildtype and G58D Sup35 increased the
number of propagons (Fig 3G and 3I, compare lanes 2 and 4). Thus, the reduction in propagon
number associated with G58D is suppressed by lowering the dosage of HSP104 and thereby
fragmentation activity, suggesting that enhanced fragmentation is the underlying mechanism.
Next, we determined if these changes in propagon number upon heterozygous disruption
of HSP104 impacted the severity and stability of the [PSI+] phenotype. Heterozygous disrup-
tion of HSP104 restored the [PSI+] phenotype (Fig 1A) and efficiently suppressed [PSI+]
loss (Fig 1D) in the [PSI+]Sc4 strains expressing any ratio of G58D. For the [PSI+]Sc37 and
[PSI+]Weak variants, similar although attenuated trends were apparent. Heterozygous disrup-
tion of Hsp104 partially reversed the pinker colony color on rich medium for both [PSI+]Sc37
and [PSI+]Weak (Fig 1B and 1C). For [PSI+]Sc37, heterozygous disruption of Hsp104 increased
[PSI+] loss in all strains, indicating that wildtype fragmentation levels must be close to the
threshold required for efficient propagation of the amyloid state (Fig 1E). Nonetheless, in the
strain expressing the 1:2 ratio of wildtype to G58D, the frequency of [PSI+] loss was suppressed
by heterozygous disruption of Hsp104 (Fig 1E). Thus, reduction of Hsp104 reverses the G58D-
induced inhibition of the [PSI+] phenotype. Together, these observations are consistent with
the idea that the downstream effect of G58D is identical for all [PSI+] variants: an enhancement
of the fragmentation efficiencies of their Sup35 amyloid.
Hsp104 mediates G58D inhibition by promoting Sup35 aggregate
disassembly
The enhanced efficiency of fragmentation of Sup35 aggregates in the presence of G58D (Fig
3D and 3E) and the reduction in propagon levels (Fig 3G and 3H) suggests that Sup35 aggre-
gates are being destroyed in strains propagating the [PSI+]Sc4 and [PSI+]Sc37 variants. For
[PSI+]Strong, we previously detected this disassembly by monitoring the soluble pool of Sup35
in response to cycloheximide treatment to follow the fate of existing protein [64]. However,
[PSI+]Strong is more sensitive to G58D expression than [PSI+]Sc4, [PSI+]Sc37 and [PSI+]Weak (Fig
1) [64], suggesting that release of soluble Sup35 from aggregates by enhanced fragmentation
may be less readily detected in the latter variants. Specifically, the individual steps in prion
propagation in vivo (e.g. conversion, fragmentation, and transmission) are variant-specific and
difficult to monitor in isolation in a living system [60,78]. Moreover, the accumulation of solu-
ble Sup35 is impacted not only by the inherent rate of conversion on fibers ends but also by
the cumulative effect of each of the steps of prion propagation on the number of those ends
[60,72]. Because the cumulative effects of each event on soluble Sup35 levels are not intuitive
to qualitatively predict from those rates, we developed a deterministic model of Sup35 dynam-
ics to deconstruct this complexity and gain additional mechanistic insight into the differential
effects of G58D on the variants. This model uses a range of conversion and fragmentation
rates that support [PSI+] maintenance to capture different variants (see S1 Text). In addition,
we have incorporated the concept of nucleation, which specifies a minimum size for a thermo-
dynamically stable aggregate and has been previously established as a key event in Sup35
aggregation in vitro [82–84].
The steady-state size and number of Sup35 aggregates reflects a balance between conver-
sion, which depends on continuous synthesis of Sup35, and fragmentation [72]; when Sup35
synthesis is halted, aggregates are predicted to increase in number (Fig 4A) and decrease in
size (Fig 4B) because fragmentation is proposed to exert a greater influence on the equilibrium
state [72]. In line with this observation, our model predicts that cycloheximide treatment will
decrease soluble Sup35 levels for prion variants that are stably propagating [PSI+] (Fig 4C)
because additional templates have been created (Fig 4A).
A common mechanism of DN prion inhibition
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Intriguingly, the extent of this decrease is predicted in our mathematical model to corre-
spond inversely with the rate of fragmentation: that is, the slowest rate of fragmentation
induces the largest decrease in soluble Sup35 (Fig 4B, black), relative to the steady-state levels
prior to the manipulation. If fragmentation produces more templates, which in turn promotes
Sup35 conversion to the amyloid state, why would we predict a lower rate of fragmentation to
have the most significant effect on soluble Sup35 levels? The reason is, as we have previously
demonstrated under heat shock conditions [85], fragmentation resolubilizes Sup35 in addition
to creating new templates. Thus, high rates of fragmentation will push the balance between
conversion and fragmentation toward the latter, causing a shift from aggregated to soluble
Sup35. Consistent with this logic, our model predicts an increase in aggregate number that
corresponds inversely with fragmentation rate (i.e. the largest increase in aggregate number
corresponds to the slowest fragmentation rate; Fig 4A, black). This correlation can be
explained directly by changes in the rate of Sup35 resolubilization from aggregates: the slowest
fragmentation rate leads to the slowest rate of resolubilization (Fig 4D, black) and thereby the
largest increase in aggregate number (Fig 4A, black).
Fig 4. Mathematical model predicts fragmentation-dependent changes in soluble Sup35 levels in
response to protein synthesis inhibition. Cycloheximide (CHX) treatment leads to an increase in the
number of aggregates (A), an increase in average aggregate size (B), and a decrease in the ratio of soluble
Sup35 (C) according to the results of stochastic simulations of a mathematical model of prion propagation.
The yields (A, C) and the rate at which protein resolubilizes (D) vary with the rates of fragmentation: high (red),
medium (blue), or low (black). The predicted changes in Sup35 average aggregate size (B) and soluble levels
(C) are lost when nucleation is removed from the model (dashed lines).
https://doi.org/10.1371/journal.pgen.1007085.g004
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These predictions correlate with our observations of the [PSI+]Sc4, [PSI+]Sc37, and [PSI+]Weak
variants upon treatment with cycloheximide. For strains where wildtype Sup35 was the only
form present, the average size of Sup35 aggregates decreased (Fig 5A–5C). In addition, the
level of soluble Sup35 decreased upon cycloheximide treatment for the [PSI+]Weak and
[PSI+]Sc37 variants, but no significant decrease was observed for [PSI+]Sc4 variant (Fig 5D–5F,
lane 1). According to our model, these observations are consistent with a nucleation-depen-
dent aggregation process, which permits resolubilization of aggregates that are fragmented
below the minimum thermodynamically stable size (Fig 4D, compare solid and dashed lines),
and a higher rate of fragmentation for [PSI+]Sc4, which would release more aggregated Sup35
into the soluble pool (Fig 4D, red). In the presence of G58D, soluble Sup35 levels in [PSI+]Sc37
and [PSI+]Weak are no longer reduced (Fig 5E and 5F, compare lanes 1 and 3), suggesting that
G58D expression promotes aggregate fragmentation and thereby resolubilization. Consistent
with this idea, treatment of the variants with both cycloheximide and guanidine HCl led to an
increase in aggregate size (Fig 5A–5C) and a decrease in soluble Sup35 levels in the presence of
G58D (Fig 5D–5F, compare lanes 3 and 4), indicating that Hsp104-catalyzed fragmentation
promotes Sup35 resolubilization.
The ability of our mathematical model to capture the behavior of Sup35 in response to
these manipulations strongly supports the idea that G58D destabilizes Sup35 aggregates to
promote their increased fragmentation by Hsp104 and thereby their resolubilization. How-
ever, a more nuanced evaluation indicates that the threshold for inhibition cannot be
explained by fragmentation efficiency alone. For example, [PSI+]Sc37 has a similar phenotypic
sensitivity to G58D dosage as the [PSI+]Sc4 variant (Fig 1) but a kinetic stability, size, and likely
fragmentation efficiency closer to the [PSI+]Weak variant (Fig 2 and S2 Fig). A bulk shift in
Sup35 from aggregate to soluble requires that the resolubilized Sup35 does not efficiently
reconvert to the aggregated state; thus, conversion efficiencies will also impact the outcome of
the G58D effects on aggregate kinetic stability, fragmentation and resolubilization. Sup35
aggregates in the [PSI+]Sc37 conformation direct conversion at a higher rate than those in the
[PSI+]Sc4 conformation [60], but the relative rates of conversion for [PSI+]Sc37 and [PSI+]Weak
have not been reported. To compare these variants, we transiently treated strains with GdnHCl
in liquid culture to reduce propagon number and then monitored propagon recovery as a
function of time after removal of GdnHCl by plating cells and assessing their colony-color
phenotype. The [PSI+]Weak variant amplified its propagons at a faster rate than the [PSI+]Sc37
variant (S4 Fig). This recovery rate is a function of the product of the conversion and fragmen-
tation rates [60]. Because Sup35 aggregates in the [PSI+]Sc37 conformation are less kinetically
stable than those in the [PSI+]Weak conformation (Fig 2B and 2D) and thereby likely frag-
mented at a higher rate, this observation suggests that the conversion rate of [PSI+]Sc37 is much
lower than that of [PSI+]Weak. As a result, resolubilized Sup35 would be less likely to reconvert
to the aggregated state in the [PSI+]Sc37 variant than in the [PSI+]Weak variant. Thus, the higher
rate of resolution and the lower rate of conversion combine to increase the sensitivity of
[PSI+]Sc37 to G58D inhibition relative to [PSI+]Weak.
G58D promotes Sup35 aggregate disassembly in daughter cells
Together, our studies are consistent with the ideas that resolubilization of aggregated Sup35 is
the mechanism of G58D inhibition and that the variant-specific rates of conversion and frag-
mentation dictate the threshold for phenotypic reversal. However, Weissman and colleagues
previously reported that loss of [PSI+]Sc4 propagated by G58D alone was associated with pro-
pagon loss from daughter but not mother cells [54]. This observation was interpreted as a
G58D-dependent defect in Sup35 aggregate transmission to daughter cells, but using a direct
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fluorescence-based microscopy assay for Sup35-GFP transmission, we were unable to detect a
transmission defect in [PSI+]Strong strains expressing wildtype and G58D Sup35 [64]. The
appearance of daughter cells without propagons could also arise if Sup35 aggregates were
transmitted but subsequently disassembled by Hsp104 in this compartment. If this scenario is
correct, inhibition of Hsp104 will lead to an increase in [PSI+] propagons in daughter cells. To
test this hypothesis, we constructed [PSI+]Sc4 diploid strains expressing only G58D Sup35 and
Fig 5. G58D expression promotes Hsp104-mediated resolubilization of aggregates. Lysates of [PSI+]Sc4 (A), [PSI+]Sc37 (B) or
[PSI+]Weak (C) strains expressing two copies of SUP35 (WT) or one wild-type and one G58D copy of SUP35 were treated with CHX or
both CHX and GdnHCl and then analyzed by SDD-AGE and immunoblotting for Sup35. Lysates from diploid [PSI+]Sc4 (D), [PSI+]Sc37
(E) or [PSI+]Weak (F) strains expressing two copies of SUP35 (WT) or one wild-type and one G58D copy of SUP35 from PtetO2 were
incubated in SDS at 53˚C or 100˚C before SDS-PAGE and quantitative immunoblotting for Sup35, and the ratio of signal before and
after treatment with CHX or both CHX and GdnHCl treatment were determined. Error bars represent standard deviations. Horizontal
lines indicate pair-wise comparisons (n 5; paired t-test, *P<0.05, **P<0.01).
https://doi.org/10.1371/journal.pgen.1007085.g005
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compared prion propagation in wildtype and HSP104 heterozygous disruption versions of this
strain by plating on rich medium and observing colony-color phenotype. Consistent with pre-
vious observations [54], [PSI+]Sc4 propagation is unstable in a wildtype strain (~50% prion
loss), but we found that this instability is strongly suppressed by heterozygous disruption of
HSP104 (~5% prion loss; Fig 6A).
Propagons are normally distributed between mother and daughter cells in a 2:1 ratio [75].
However, analysis of propagon numbers in mother and daughter cells showed an even stron-
ger bias in the distribution of propagons toward the mothers in the presence of G58D (Fig 6B,
black diamonds), including a population of pairs in which the mother but not the daughter
retained a large number of propagons (Fig 6B, red diamonds). By contrast, heterozygous dis-
ruption of HSP104 reduced the stronger mother bias associated with G58D expression, and
more propagons were detected in daughter cells (Fig 6B, white triangles). Notably, daughter
cells lacking propagons were not isolated from the HSP104 heterozygous disruption strain,
indicating that the suppression of prion loss (Fig 6A) correlated with an increase in propagons
in daughter cells (Fig 6B).
Given the suppression of these phenotypes by heterozygous disruption of Hsp104, we next
directly determined if Hsp104 inhibition specifically in daughter cells is sufficient to suppress
[PSI+] loss. To do so, we isolated daughter cells from [PSI+]Sc4 diploids expressing one copy
each of wildtype and G58D SUP35 by FACS, based on the staining of bud scars with Alexa-647
WGA. The absence of bud scars in cells with the lowest fluorescence intensity indicates that
this fraction contains the newborn population, in contrast to a mixed population before sort-
ing (Fig 6C and S5 Fig). The isolated daughters were then incubated on rich medium in the
presence or absence of GdnHCl for three hours to transiently inhibit Hsp104 activity and then
plated to determine the frequency of prion loss. Strikingly, GdnHCl treatment of daughter
cells suppressed the frequency of prion loss (Fig 6D). Because daughter cells were biochemi-
cally isolated before treatment, the GdnHCl suppression of prion loss cannot be explained by
an increased transmission of Sup35 aggregates to daughter cells upon Hsp104 inhibition.
Rather, Sup35 aggregates must have already been present, with the transient inhibition of
Hsp104 blocking their resolubilization after transfer, consistent with the idea that G58D inhib-
its the propagon of all [PSI+] variants through the same mechanism.
Discussion
Together, our studies indicate that a single inhibitor, the dominant-negative G58D mutant of
Sup35, can perturb the propagation of four different variants of the [PSI+] prion, [PSI+]Strong,
[PSI+]Sc4, [PSI+]Sc37, and [PSI+]Weak, through the same mechanism. The effects of G58D
expression are most easily detected at the protein level as kinetic destabilization of Sup35 amy-
loid (Fig 3A–3C) and related reductions in the size of their SDS-resistant core polymers (Fig
3D–3F). These changes only become apparent at the phenotypic and inheritance levels when
the impact on Sup35 amyloid rises above a threshold dictated by the rates of conversion and
fragmentation for the variants, allowing disassembly to dominate over reassembly.
The G58D mutation lies in the second oligopeptide repeat of Sup35, a region of the protein
that is essential for prion propagation [86–88] and that impacts the ability of the Hsp104 chap-
erone to thread monomers through its central pore during the fragmentation process [89].
Position 58 is located within the amyloid core of Sup35 in the [PSI+]Sc37 variant but is more
accessible in the [PSI+]Sc4 variant [69]. Nonetheless, the kinetic destabilization of the four vari-
ants by G58D (Fig 3A–3C) [64] suggests this region contributes directly to associations within
each of the aggregates. Structural studies on the isolated second repeat revealed that the G58D
substitution introduced a turn into the otherwise extended conformation of the wildtype
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repeat, suggesting that packing and thereby amyloid kinetic stability could be altered by this
conformational change [90].
Previous studies on the [PSI+]Strong and [PSI+]Sc4 conformational variants suggested two
different mechanisms for G58D-induced curing. For [PSI+]Strong, curing depended not only
on the dosage of G58D but also of HSP104, suggesting that prion propagation was inhibited by
amyloid disassembly. Indeed, in the presence of G58D, previously aggregated Sup35
Fig 6. Hsp104 promotes [PSI+] curing in daughter cells expressing G58D. (A) Spontaneous frequencies of [PSI+]Sc4 loss during
mitotic division were determined by counting the percentage of [psi-] colonies for strains that were wildtype (+) or heterozygous disruptions
for HSP104 (Δ). For each strain, >3000 colonies were scored. Error bars represent standard deviations from 10 biological replicates. (B)
The number of propagons in daughter cells was plotted against the number of propagons in mother cells for wildtype (HSP104/+, black or
red diamonds) or heterozygous HSP104 disruption (HSP104/Δ, white triangles) diploid strains expressing one copy of G58D from PSUP35
and another copy of G58D from PADH in an [PSI+]Sc4 strain. Red diamonds represent mother-daughter pairs in the wildtype strain in which
the mother contained propagons but the daughter did not. (C) The distribution of fluorescence intensities for a population of [PSI+]Sc4 diploid
cells expressing one endogenous copy of SUP35 and a second copy of SUP35 (G58D) from PSUP35 stained with Alexa-647 WGA was
obtained by flow cytometry. Vertical dotted lines indicate least fluorescent 5%, which was sorted as daughters. (D) The daughters isolated
in (C) were plated onto minimal medium containing 3mM GdnHCl for three hours and then transferred to rich medium. The frequency of
[PSI+] loss was then determined relative to that from daughters isolated from the same culture plated directly onto rich medium. Horizontal
lines indicate pair-wise comparisons (n10 cells per strain; paired t-test, ***P<0.001).
https://doi.org/10.1371/journal.pgen.1007085.g006
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transitioned to the soluble fraction [64]. For [PSI+]Sc4, curing correlated with the loss of herita-
ble aggregates in daughter cells, interpreted as a G58D-induced defect in amyloid transmission
[54]. These distinct models for inhibition are consistent with the idea that different conforma-
tional variants must be cured through different molecular mechanisms [62,63]. However, our
studies resolve this controversy: G58D inhibits both variants by promoting amyloid disassem-
bly in daughter cells. This model is supported by both the Hsp104-dependence of the curing of
both variants (Fig 1D) [64] and of the reduction in propagons (Fig 3H) [64]. In addition, over-
expression of Hsp104 cures [PSI+]Sc4 propagated by G58D but not wildtype Sup35, suggesting
the former is more sensitive to higher fragmentation rates than the latter [54]. Consistent with
this interpretation, overexpression of an N-terminally truncated Hsp104 mutant [54], which is
deficient in substrate processing [91], is unable to cure [PSI+]Sc4 propagated by G58D.
We have previously drawn parallels between the dominant-negative inhibition of [PSI+]
propagation by Sup35 G58D and that of protease-resistant PrP by hamster Q219K (corre-
sponding to E219K in humans and Q218K in mouse). In both cases, the mutant is incorpo-
rated into wildtype aggregates but capable of destabilizing the amyloid state only when present
in excess to wildtype protein, and the efficacy of dominant-negative inhibition is greater for
less kinetically stable conformational variants [15,20,21,64,92]. Given the likelihood that the
mechanisms of inhibition are similar between the yeast and mammalian dominant-negative
mutants, the “resistance” of sCJD to E219K in humans and of 22L to Q219K in mice may be
possible to overcome by increasing the dosage of the mutant, as we have demonstrated here
for G58D and [PSI+]Sc37 (Fig 1B and 1E). For G58D, inhibition occurs at a dosage far below
that at which the prion state is induced to appear [53], indicating that the threshold between
curing and induction is wide enough to accommodate switches in one direction or the other
specifically. A similar analysis in mammals would be prudent before pursuing increased dos-
age of dominant-negative mutants as a therapeutic strategy.
How can the absence of heritable aggregates in some daughter cells be reconciled with amy-
loid disassembly as a common mechanism of inhibition for G58D? Our previous studies have
revealed that increasing chaperone levels by heat shock, leads to amyloid disassembly in a
[PSI+]Weak strain [85], suggesting that the ratio of chaperones:amyloid is a key contributor to
the balance between amyloid assembly and disassembly. A similar skew in this ratio likely
occurs during G58D curing but through a distinct mechanism. Our previous studies uncov-
ered a size threshold for amyloid transmission during yeast cell division: larger aggregates
were preferentially retained in mother cells [72]. This asymmetry created an age-dependent
difference in aggregate load, with newborn daughters taking several generations to return to
the steady-state level of propagons observed in mother cells [72]. This observation suggests
that the chaperone:substrate ratio could be skewed toward the former in daughter cells. This
altered ratio, when combined with the decrease in the kinetic stability of Sup35 amyloid
induced by G58D (Fig 3A–3C), likely creates a niche where amyloid disassembly dominates.
Indeed, the normally resistant [PSI+]Strong variant is cured by transient heat shock when G58D
is expressed [85]. Consistent with the idea that G58D cures [PSI+] by promoting amyloid disas-
sembly, curing is reduced (Fig 5A), and propagon numbers increase in daughters (Fig 5B)
when Hsp104 levels are reduced. Most importantly, transiently blocking Hsp104 activity in
daughter cells after division also greatly reduces prion loss (Fig 5D). Thus, G58D–containing
Sup35 amyloid is transmitted to daughter cells, but, once there, these aggregates are at greater
risk of clearance by Hsp104-mediated disassembly.
Beyond dominant-negative mutants, conformational variants of PrP and Sup35 also differ
in their sensitivities to small molecule inhibitors [62,63]. Unfortunately, even sensitive confor-
mational variants can develop resistance to these compounds, further complicating attempts
to develop therapeutic interventions for these diseases. For example, treatment of prion-
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infected mice or tissue culture cells with quinacrine or swainsonine reduced the kinetic stabil-
ity of protease-resistant PrP and altered its tropism in cell lines, but these properties were
reversed when treatment was removed [93–95]. Although it remains unclear whether the
emerging conformational variants were minor components that were selected or newly
induced by the treatment, this conformational plasticity creates a moving target that is impos-
sible to manage if a unique inhibitor must be developed in each case. Our studies suggest that
as prion conformational variants evolve, adapt or mutate, changes in dosing regimes could be
effective countermeasures, although the range of possible doses is likely to be restricted
because overexpression of even a dominant-negative mutant can lead to prion appearance
[53]. Nevertheless, quinacrine can eliminate the RML conformational variant of PrP from
CAD5 cells at a 5-fold lower dosage than is required to eliminate an IND24-resistant variant
[96].
Much research is focused on the appearance and self-replicating amplification of amyloid,
yet these processes are clearly counteracted by disassembly pathways in vivo. This balance
between assembly and disassembly contributes strongly to prion persistence, even in mam-
mals. For example, inhibition of PrP expression can reverse accumulation of protease-resistant
PrP, pathological changes and clinical progression of prion disease in mice, presumably by
allowing clearance pathways to dominate, if initiated before extensive damage arises [97].
While mammals lack an Hsp104 homolog, a chaperone system, composed of mammalian
Hsp70, Hsp110, and class A and B J-proteins, possesses strong disaggregase activity [98], capa-
ble of directing amyloid disassembly, although this activity has yet to be tested against prote-
ase-resistant PrP [99]. Nevertheless, natural variations in the accumulation of prion and
chaperone proteins may also serve as a new framework in which to consider phenotypic differ-
ences among variants. For example, tropism and clinical progression are likely to be impacted
by the balance between assembly and disassembly pathways, as we have observed for mitotic
stability and heat shock-induced prion curing in yeast [72,85]. Moreover, the steady-state ratio
of chaperones:amyloid may be a key consideration in screening potential therapeutics and in
their ultimate efficacy in vivo, particularly for small molecules proteostasis regulators that per-
turb the assembly/disassembly balance.
Methods
Plasmids
All plasmids used in this study are listed in S1 Table. pRS306-PADH contains PADH-Multiple
Cloning Site-TCYC1 as a KpnI-SacI fragment from pSM556 (a gift from F.U. Hartl) in a simi-
larly digested pRS306. The SUP35(G58D) ORF was then subcloned into pRS306-PADH as a
BamHI-EcoRI fragment isolated from pRS306-SUP35(G58D) to create pRS306-PADHSUP35
(G58D) (SB468).
Oligonucleotides
Oligonucleotides used in this study are listed in S2 Table.
Yeast strains
All strains are derivatives of 74-D694 and are listed in S3 Table. [PSI+]Sc4 (SY2085) and
[PSI+]Sc37 (SY2086) haploid wildtype strains were gifts from J. Weissman. Yeast strains
expressing ectopic copies of SUP35 or G58D from URA3 (pRS306) or TRP1 (pRS304)-marked
plasmids were constructed by transforming yeast strains with plasmids that were linearized
with BstBI or Bsu361, respectively, and by selecting for transformants on the appropriate
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minimal medium. In all cases, expression was confirmed by quantitative immunoblotting for
Sup35. Disruptions of SUP35 (FP35, FP36) were generated by transformation of PCR-gener-
ated cassettes using pFA6aKanMX4 as a template with the indicated oligonucleotide primers
(S2 Table) and selection on rich medium supplemented with G418. HSP104 disruptions were
generated by transformation with a PvuI-BamHI fragment of pYABL5 (a gift from S. Lind-
quist) and selection on minimal medium lacking leucine. Disruptions of NAT1 (FP29, FP30)
were generated by transformation of PCR-generated cassettes using pFA6a-hphMX4 as a tem-
plate with the indicated primers (S2 Table) and selection on complete medium supplemented
with hygromycin. All the disruptions were verified by PCR and 2:2 segregation of the appro-
priate marker.
Prion loss
Exponentially growing cultures of the indicated strain were plated on YPD for single colonies,
and the frequency of [PSI+] loss was determined by the number of red colonies arising.
Protein analysis
Semidenaturing detergent agarose gel electrophoresis (SDD-AGE), SDS-PAGE, quantitative
immunoblotting and SDS-sensitivity experiments were performed as previously described
[73]. To analyze the fate of aggregated Sup35, cultures were grown to midlog phase and treated
with cycloheximide (CHX) or both CHX and guanidine HCl (GdnHCl) for 1.7 hours. Yeast
lysates were collected before and after treatment and incubated at 53˚C and 100˚C in the pres-
ence of 2% SDS before analysis by SDS-PAGE. Lysates were also prepared from the same cul-
tures and analyzed by SDD-AGE.
Propagon counts
The number of propagons per cell was determined using a previously described in vivo dilu-
tion, colony-based method [75]. For propagon counting in mothers and daughters, a pair of
mother and daughter cells was separated by micromanipulation onto minimal medium (SD-
complete with 2.5mM adenine and 4% dextrose) with 3mM GdnHCl. After growing at 30˚C
for about 48 h, whole colonies were isolated using a cut pipette tip, resuspended in a small vol-
ume of water and plated onto YPD plates. The number of white colonies was then counted.
Daughter-specific assays
Daughters were separated by FACS based on bud-scar labeling. Yeast cells were incubated for
1 h at room temperature in 1μg/ml Alexa-647 wheat germ agglutinin (WGA) in PBS. After
washing twice in PBS, cells with the lowest fluorescence intensity (5%) were sorted as newborn
daughter cells, and a sample of this fraction was viewed by fluorescence microscopy to confirm
bud scar number. This fraction was also moved to rich medium (1/4 YPD) for color develop-
ment. For Hsp104 inhibition, sorted fractions were first moved to a minimal medium with
3mM GdnHCl for three hours before being transferred to rich medium. In each case only
completely red colonies were counted as [psi-].
Fluorescence microscopy
Fluorescence microscopy was performed on a DeltaVision deconvolution microscope
equipped with a 100x objective. WGA Alexa-647 fluorescence was collected using 650nm exci-
tation and 668nm emission wavelengths and with an exposure of 50ms. Images were processed
in ImageJ software.
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Propagon recovery
Cultures were grown in YPAD medium to an OD600 of 0.1 at 30˚C. GdnHCl was added to
3mM, and the culture was returned to 30˚C for 5 hours to decrease the propagon number. Cul-
tures were then collected by centrifugation, washed and transferred to YPAD medium without
GdnHCl for recovery. Samples were plated on YPD, and the number of propagons per cell was
counted at the indicated timepoints.
Supporting information
S1 Fig. Sup35 expression level is consistent with copy number. Lysates isolated from
[PSI+]Sc4 (A), [PSI+]Sc37 (B) or [PSI+]Weak (C) strains described in Fig 1A–1C were analyzed by
SDS-PAGE and quantitative immunoblotting for Sup35. The ratio of Sup35 relative to a wild-
type diploid is shown. Error bars represent standard deviation.
(TIF)
S2 Fig. [PSI+] variants differ in the size of their Sup35 aggregates. Lysates from the indicated
[PSI+] variant haploid yeast strains were analyzed by SDD-AGE and immunoblotting for
Sup35.
(TIF)
S3 Fig. Hsp104 expression level is consistent with copy number. Lysates isolated from
[PSI+]Sc4 (A), [PSI+]Sc37 (B) or [PSI+]Weak (C) strains described in Fig 1A–1C were analyzed by
SDS-PAGE and quantitative immunoblotting for Hsp104. The ratio of Hsp104 relative to a
wild-type diploid is shown. Error bars represent standard deviation.
(TIF)
S4 Fig. [PSI+]Sc37 and [PSI+]Weak recover propagons at different rates. The rate of propagon
recovery was determined for [PSI+]Sc37 (blue) and [PSI+]Weak (red) after treatment with
GdnHCl. Error bars represent standard deviation. (n 12 cells per strain per time point;
unpaired t-test, P<0.01).
(TIF)
S5 Fig. Analysis of FACS-sorted daughter cells. DIC and Alexa-647 WGA fluorescence of
bud scars of cells both before and after FACS sorting. Scale bars represent 3μm.
(TIF)
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